Fortress Biotech Stock Quote FBIO - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

1.73

Bid

1.73

Ask

1.74

Volume

24,682

1.71 Day's Range 1.79

1.24 52 Week Range 11.85

Market Cap

31.792M

Previous Close

1.72

Open

1.71

Last Trade

1.73

Last Trade Time

11:52:19

Financial Volume

$ 42,889

VWAP

1.7377

Average Volume (3m)

293,782

Shares Outstanding

18,376,750

Dividend Yield

PE Ratio

-0.46

Earnings Per Share (EPS)

-3.74

Revenue

84.51M

Net Profit

-68.67M

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Targadox, Exelderm, Ceracade, Luxamend, and Dermasorb. The business activities of the g... Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Targadox, Exelderm, Ceracade, Luxamend, and Dermasorb. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.fortressbiotech.com

Headquarters

Dover, Delaware, USA

Founded

1970

Fortress Biotech Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker FBIO. The last closing price for Fortress Biotech was $1.72. Over the last year, Fortress Biotech shares have traded in a share price range of $ 1.24 to $ 11.85.

Fortress Biotech currently has 18,376,750 shares outstanding. The market capitalization of Fortress Biotech is $31.79 million. Fortress Biotech has a price to earnings ratio (PE ratio) of -0.46.

Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024

SCOTTSDALE, Ariz., April 25, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily...

Avenue Therapeutics Announces Reverse Stock Split

MIAMI, April 24, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and...

Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights

Record consolidated net revenue of $84.5 million for full-year 2023 Fortress may receive up to four regulatory decisions on NDAs and BLAs in the next 18 months FDA accepted New Drug Application...

Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Planning for proof-of concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 CD20-targeted CAR T-cell therapy in autoimmune diseases is underway and expected to initiate in the...

Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024

MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and...

Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Company generated total revenues of $79.2 million for the full year ended December 31, 2023, a 7% increase from the $73.7 million reported in 2022 Achieved $15.6 million in operating cost savings...

Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights

- Enrollment completed in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data expected in second quarter of 2024 - - Presented positive BAER-101 preclinical...

Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea

SCOTTSDALE, Ariz., March 18, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily...

Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024

SCOTTSDALE, Ariz., March 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on...

Avenue Therapeutics Receives Positive Listing Determination from Nasdaq

MIAMI, March 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.13	-6.98924731183	1.86	1.86	1.66	170752	1.7614486	CS
4	-0.32	-15.6097560976	2.05	2.053	1.6306	232170	1.84011044	CS
12	-0.22	-11.2820512821	1.95	2.615	1.63	293782	1.92657606	CS
26	-0.15	-7.97872340426	1.88	4.43	1.24	562374	2.2851229	CS
52	-9.22	-84.200913242	10.95	11.85	1.24	559505	5.0622591	CS
156	-63.07	-97.3302469136	64.8	71.85	1.24	535425	20.90644586	CS
260	-24.67	-93.446969697	26.4	91.5	1.24	653361	35.56978219	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
BDRXBiodexa Pharmaceuticals PLC	$ 1.223 (68.74%)	57.15M
NIVFNewGenIvf Group Ltd	$ 1.9699 (51.53%)	49.95M
PEGYPineapple Energy Inc	$ 0.0729 (40.46%)	258.45M
ULHUniversal Logistics Holdings Inc	$ 45.38 (37.98%)	306.67k
SBFMSunshine Biopharma Inc	$ 1.10 (36.24%)	16.99M
ISUNiSun Inc	$ 0.165 (-95.21%)	7.65M
NWGLNature Wood Group Ltd	$ 5.7079 (-66.13%)	818.16k
ICLKiClick Interactive Asia Group Ltd	$ 1.4012 (-44.62%)	574.92k
NUWENewellis Inc	$ 0.1793 (-37.96%)	15.37M
SGBXSafe and Green Holdings Corporation	$ 0.1544 (-29.50%)	5.4M
PEGYPineapple Energy Inc	$ 0.0729 (40.46%)	258.45M
SQQQProShares UltraPro Short QQQ	$ 11.4201 (-4.83%)	83.96M
INTCIntel Corporation	$ 32.16 (-8.40%)	66.96M
BDRXBiodexa Pharmaceuticals PLC	$ 1.223 (68.74%)	57.15M
TSLATesla Inc	$ 171.0413 (0.51%)	52.98M